Circulating Tumor DNA Dynamics Reveal KRAS G12C Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors
Authors:
- Yoonha ChoiYCYoonha Choi
- Neekesh V. DhariaNDNeekesh V. Dharia
- Tomi JunTJTomi Jun
- Julie ChangJCJulie Chang
- Stephanie Royer-JooSRStephanie Royer-Joo
- Kenneth K. YauKYKenneth K. Yau
- Zoe J. AssafZAZoe J. Assaf
- Junko AimiJAJunko Aimi
- Smruthy SivakumarSSSmruthy Sivakumar
- Meagan MontesionMMMeagan Montesion
- Adrian SacherASAdrian Sacher
- Patricia LoRussoPLPatricia LoRusso
Open Access
- 12 July 2024
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 30 (17) , 3788-3797
Abstract
Purpose: To inform prognosis, treatment response, disease biology, and KRAS G12C mutation heterogeneity, we conducted exploratory circulating tumor DNA (ctDNA) profiling on 134 patients with solid tumors harboring a KRAS G12C mutation treated with single-agent divarasib (GDC-6036) in a phase 1 study. Experimental Design: Plasma samples were collected for serial ctDNA profiling at baseline (cycle 1 day 1 prior to treatment) and multiple on-treatment time points (cycle 1 day 15 and cycle 3 day 1). Results: KRAS G12C ctDNA was detectable from plasma samples in 72.9% (43/59) and 92.6% (50/54) of patients with non–small cell lung cancer and colorectal cancer, respectively, the majority of whom were eligible for study participation based on a local test detecting the KRAS G12C mutation in tumor tissue. Baseline ctDNA tumor fraction was associated with tumor type, disease burden, and metastatic sites. A decline in ctDNA level was observed as early as cycle 1 day 15. Serial assessment showed a decline in ctDNA tumor fraction associated with response and progression-free survival. Except for a few cases of KRAS G12C sub-clonality, on-treatment changes in KRAS G12C variant allele frequency mirrored changes in the overall ctDNA tumor fraction. Conclusions: Across tumor types, the KRAS G12C mutation likely represents a truncal mutation in the majority of patients. Rapid and deep decline in ctDNA tumor fraction was observed in patients responding to divarasib treatment. Early on-treatment dynamics of ctDNA were associated with patient outcomes and tumor response to divarasib treatment.Keywords
All Related Versions
This publication has 33 references indexed in Scilit:
- Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast CancerJournal of Clinical Oncology, 2018
- Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumorsNature Communications, 2017
- Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder CancerClinical Cancer Research, 2017
- RAS Proteins and Their Regulators in Human DiseaseCell, 2017
- Tracking the Evolution of Non–Small-Cell Lung CancerNew England Journal of Medicine, 2017
- Phylogenetic ctDNA analysis depicts early-stage lung cancer evolutionNature, 2017
- Liquid biopsies come of age: towards implementation of circulating tumour DNANature Reviews Cancer, 2017
- Circulating DNA as a Strong Multimarker Prognostic Tool for Metastatic Colorectal Cancer Patient Management CareClinical Cancer Research, 2016
- Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical TrialsClinical Cancer Research, 2016
- Circulating mutant DNA to assess tumor dynamicsNature Medicine, 2008